[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know",
    "summary": "AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=140ad610cca8b2e7931f1cebc00485ae3efff446cb9282f036b0ceed7526d8ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761169502,
      "headline": "AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know",
      "id": 137197819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=140ad610cca8b2e7931f1cebc00485ae3efff446cb9282f036b0ceed7526d8ba"
    }
  },
  {
    "ts": null,
    "headline": "Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation",
    "summary": "We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss. Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield. […]",
    "url": "https://finnhub.io/api/news?id=d2b864cd2669eafd5c6aa8ba8afde2c54d243c6549ffdf80cd91dd54c3917767",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761162286,
      "headline": "Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation",
      "id": 137191876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss. Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield. […]",
      "url": "https://finnhub.io/api/news?id=d2b864cd2669eafd5c6aa8ba8afde2c54d243c6549ffdf80cd91dd54c3917767"
    }
  },
  {
    "ts": null,
    "headline": "Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative",
    "summary": "AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib) was significantly more effective than Humira (adalimumab) in achieving low disease activity and remission for adults with moderate to severe rheumatoid arthritis who previously did not respond to a TNF inhibitor. This outcome highlights Rinvoq’s potential to become a more central immunology offering for AbbVie as Humira encounters increased biosimilar...",
    "url": "https://finnhub.io/api/news?id=b61d6ddf239b222844e5998492260ae78498ebf60ebaa3c01d2c3cced13219cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761160488,
      "headline": "Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative",
      "id": 137191877,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib) was significantly more effective than Humira (adalimumab) in achieving low disease activity and remission for adults with moderate to severe rheumatoid arthritis who previously did not respond to a TNF inhibitor. This outcome highlights Rinvoq’s potential to become a more central immunology offering for AbbVie as Humira encounters increased biosimilar...",
      "url": "https://finnhub.io/api/news?id=b61d6ddf239b222844e5998492260ae78498ebf60ebaa3c01d2c3cced13219cb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance. AbbVie is advancing its oncology […]",
    "url": "https://finnhub.io/api/news?id=618e2986d00770b854bd2eacfadce66774a2c38d206b51fdd2fd0d62ed0425e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761157884,
      "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
      "id": 137191878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance. AbbVie is advancing its oncology […]",
      "url": "https://finnhub.io/api/news?id=618e2986d00770b854bd2eacfadce66774a2c38d206b51fdd2fd0d62ed0425e8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0ecdd81124b51a7e1f1d19a6583c5067942f8059c3165ecf9fe691b51b0087cd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761150660,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 137225450,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0ecdd81124b51a7e1f1d19a6583c5067942f8059c3165ecf9fe691b51b0087cd"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Up More Than 30% in 6 Months: How to Play the Stock",
    "summary": "AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.",
    "url": "https://finnhub.io/api/news?id=c5478020a0a180250eee2286239d697b9f2bfdb30270368d7c77ab439e109122",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761143340,
      "headline": "AbbVie Up More Than 30% in 6 Months: How to Play the Stock",
      "id": 137187813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.",
      "url": "https://finnhub.io/api/news?id=c5478020a0a180250eee2286239d697b9f2bfdb30270368d7c77ab439e109122"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=fbce954da9774af96f3af8a17d5ae4bbaa384ef477ebfab28c6cae9edded26a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761138005,
      "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
      "id": 137187814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=fbce954da9774af96f3af8a17d5ae4bbaa384ef477ebfab28c6cae9edded26a5"
    }
  }
]